Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of treatment options and benefits for Non-small cell cancer patients with uncommon EGFR mutations treated with Atezolizumab plus bevacizumab and chemotherapy

Next Previous
Trial Profile

Assessment of treatment options and benefits for Non-small cell cancer patients with uncommon EGFR mutations treated with Atezolizumab plus bevacizumab and chemotherapy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary) ; Afatinib; Osimertinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

Most Recent Events

  • 01 Dec 2022 Results assessing efficacy of atezolizumab plus bevacizumab and chemotherapy in patients with NSCLC with uncommon EGFR mutations published in the Lung Cancer
  • 21 Jul 2022 New trial record
  • 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top